1 – 49 of 49
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
(
- Contribution to journal › Article
- 2023
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes
2023) In Lund University, Faculty of Medicine, Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
- 2022
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
(
- Contribution to journal › Article
-
Mark
Long-term joint outcomes in adolescents with moderate or severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Alternative payment models for durable and potentially curative therapies : The case of gene therapy for haemophilia A
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
- 2021
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B
(
- Contribution to journal › Scientific review
- 2019
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
(
- Contribution to journal › Article
- 2018
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction : What have we learned over time?
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
(
- Contribution to journal › Article
- 2017
-
Mark
Primary prophylaxis in haemophilia care : Guideline update 2016
(
- Contribution to journal › Article
-
Mark
European retrospective study of real-life haemophilia treatment
(
- Contribution to journal › Article
-
Mark
Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics
(
- Contribution to journal › Article
-
Mark
Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
(
- Contribution to journal › Article
- 2016
-
Mark
Inhibitor development in previously untreated patients with severe haemophilia A : a nationwide multicentre study in Finland
(
- Contribution to journal › Article
-
Mark
Potential biomarkers of haemophilic arthropathy : correlations with compatible additive magnetic resonance imaging scores
(
- Contribution to journal › Article
- 2015
-
Mark
How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access
(
- Contribution to journal › Article
- 2014
-
Mark
Similar bleeding phenotype in young children with haemophilia A or B : A cohort study
(
- Contribution to journal › Article
- 2010
-
Mark
Clinical issues in inhibitors
(
- Contribution to journal › Scientific review
- 2008
-
Mark
Management of carriers and babies with haemophilia
(
- Contribution to journal › Article
-
Mark
Surgical evaluation of a recombinant factorVIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients
(
- Contribution to journal › Article
-
Mark
Venous Access in Children with Inhibitors
2008) p.36-41(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2007
-
Mark
The risk associated with indwelling catheters in children with haemophilia.
(
- Contribution to journal › Scientific review
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate((R)) P/Humate-P((R))) in von Willebrand Disease and Haemophilia A: A Viewpoint by Eric Berntorp.
(
- Contribution to journal › Letter
- 2006
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article
- 2005
-
Mark
Changing pattern of care of boys with haemophilia in western European centres
(
- Contribution to journal › Article
- 2004
-
Mark
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
(
- Contribution to journal › Article
- 2003
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
- 2002
-
Mark
Inhibitors in the Swedish population with severe haemophilia A and B : A 20-year survey
(
- Contribution to journal › Article
- 1999
-
Mark
Origin of mutation in sporadic cases of haemophilia A
(
- Contribution to journal › Article
-
Mark
Prenatal diagnosis of haemophilia
(
- Contribution to journal › Scientific review
- 1998
-
Mark
Prophylactic treatment in Sweden - Overtreatment or optimal model?
(
- Contribution to journal › Article
-
Mark
Can haemophilic arthropathy be prevented?
(
- Contribution to journal › Special issue (editor)
-
Mark
Port-A-Cath usage in children with haemophilia : Experience of 53 cases
(
- Contribution to journal › Article
- 1997
-
Mark
Pharmacokinetic dosing of factor VIII and factor IX in prophylactic treatment of haemophilia
1997)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
(
- Contribution to journal › Article
- 1995
-
Mark
The impact of prenatal diagnosis on the incidence of haemophilia in Sweden
(
- Contribution to journal › Article
- 1994
-
Mark
Normal vaginal delivery is to be recommended for haemophilia carrier gravidae
(
- Contribution to journal › Article
- 1991
-
Mark
More than half the sporadic cases of Hemophilia A in Sweden are due to a recent mutation
(
- Contribution to journal › Article
- 1990
-
Mark
Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases
(
- Contribution to journal › Article